NITROSOUREA DERIVATIVES, A PROCESS FOR PREPARING SAME AND THERAPEUTIC COMPOSITIONS

Abstract: Nitrosourea compounds of the formula: wherein R¹ is lower alkyl and R² is lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy-lower alkyl, which may be prepared by nitrosation of a compound of the formula: wherein R¹ and R² are the same as defined above. Said nitrosourea compounds are useful as an anti-tumor or anti-leukemic agent.

Description: Nitrosourea derivatives, a process for preparing same and therapeutic compositions This invention relates to nitrosourea derivatives., a process for preparing same and therapeutic compositions. More particularly, it relates to compounds of the formula: EMI1.1 wherein R1 is lower alkyl and R2 is lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy-lower alkyl. It is known that 1-(2-chloroethyl)-1-nitroso-3-ss-(D-manno- pyranosyl)urea and 1-(2-chloroethyl)1-nitroso-3-ss(D-gluco pyranosyl)urea (The latter compound being hereinafter referred to as "GANU) increase the life span of mice implanted intraperitoneally with the tumor cells of lymphoid leukemia L-1210 (U.S. Patent No. 4086415). It is also known that 1-(2-chloroethyl)-1-nitroso-3-ss-(D-lactosyl)urea and 1-(2 chloroethyl)-1-nitroso-3-ss-(D-maltosyl)urea show anti-tumor activity against leukemic cells (Japanese Patent Publication (unexamined) No. 141815/1976). We have now found that the nitrosourea compound (I) of the present invention shows potent anti-tumor or anti-leukemic activity and is useful to inhibit the growth of malignant tumor cells in warm-blooded animals. For example, when the anti-tumor effects upon leukemia is estimated by administering such drugs intraperitoneally to tumor cell-inoculated mice (i.e., mice implanted with tumor cells of leukemia L-1210) for five consecutive days, 1-(2-chloroethyl)-1-nitroso-3methyl-3-(methyl 3-deoxy--D-glucopyranosid-3-yl ) urea at the daily dose of 0.26 mg/kg shows an increase of about 30 % in the average life span of said mice. Moreover, the compound (I) may show an excellent therapeutic index estimated in terms of ratio of M.T.D. (the maximum tolerated dose which shows 100 % inhibition for the growth of Ehrlich ascites tumor in mice without causing the death of said mice) to M.E.D. (the minimum effective dose which shows 100 % inhibition for the growth of said ascites tumor). For example, said therapeutic indexes (M.T.D./M.E.D.) of 1-(2-chloroethyl)-1nitroso-3-isobutyl-3-(methyl 3-deoxy-u-D-glucopyranosid- 3-yl)urea, 1-(2-chloroethyl)-1-nitroso-3-allyl-3-(methyl 3 deoxy-i-D-glucopyranosid-3-yl)urea and 1-( 2-chloroethyl ) -1- nitroso-3- (2-methoxyethyl)-3-(methyl 3-deoxy-W-D-glucopyranosid 3-yl)urea are 4 times greater than that of GANU. In the above-mentioned formula (I), representative examples of the group R1 include lower alkyl such as methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyi, sec-butyl and t-butyl. On the other hand, representative examples of the 2 group R include lower alkyl such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-amyl, isoamyl, secamyl, and t-amyl; lower.alkenyl such as vinyl, allyl, butenyl and pentenyl; lower alkynyl such as ethynyl, propargyl, butynyl and pentynyl; lower alkoxy-lower alkyl such as methoxymethyl, methoxyethyl, methoxy-n-propyl, methoxy-n-butyl, methoxy-n-pentyl, ethoxymethyl, ethoxyethyl, ethoxy-n-propyl, ethoxy-n-butyl and ethoxy-n-pentyl. Further, among those of the invention, a preferred subgenus includes the compound of the formula (I) in which R1 is methyl, and R2 is methyl, n-butyl, isobutyl, allyl, propargyl, methoxyethyl or methoxy-n-propyl. According to the present invention, the nitrosourea compound (I) is prepared by nitrosation of a compound of the formula: EMI4.1 wherein R1 and R2 are the same as defined above. The starting compound (II) is readily obtained. For example, it can be prepared by condensing a compound of the formula: EMI4.2 wherein R1 is the same as defined above, with a primary amine of the formula: Rê-NH2 (wherein Rê is the same as defined above) at 120 to 1800C to give a compound of the formula: EMI4.3 wherein RÚ and Rê are the same as defined above, and then condensing the compound (IV) with 2-chloroethyl isocyanate at 0 to 250C in an inert solvent (e.g., methanol, ethanol, tetrahydrofuran). If required, the condensation of the compound (III) and the primary amine may be carried out in an inert solvent such as methanol or ethanol. The nitrosation reaction of the present invention is accomplished by contacting the compound (II) with nitrous acid, nitrogen trioxide or nitrogen tetroxide in an inert solvent. The reaction can be preferably carried out at a temperature of -20 to 200C, especially at about -10 to 0 C. Water, tetrahydrofuran, methylene chloride, ethyl acetate, acetic acid, and formic acid are suitable as the inert solvent. When free nitrous acid is prepared by reacting an alkali metal salt of nitrous acid (e.g., sodium nitrite, potassium nitrite) or a lower alkyl ester thereof (e.g., butyl nitrite, amyl nitrite) with a mineral or organic acid (e.g., hydrochloric acid, sulfuric acid, formic acid or acetic acid), it is preferred that said free nitrous acid is employed for subsequent nitrosation reaction immediately after preparation thereof. On the other hand, when nitrogen trioxide or nitrogen tetroxide is employed in the invention, it is preferred to carry out the nitrosation reaction by dissolving or suspending the starting compound (II) in the inert solvent and then introducing gaseous nitrogen trioxide or tetroxide thereto in presence or absence of an acid acceptor. Sodium bicarbonate, sodium carbonate, potassium carbonate, sodium acetate, potassium acetate are suitable as the acid acceptors. When the nitrosation reaction is completed, the compound (I) of the invention is readily recovered from the reaction mixture and may be, if required, further purified by silica gel chromatography. The nitrosourea compound (I) thus obtained shows potent anti-tumor activity against various tumor cells such as Ehrlich's carcinoma, Sarcoma 180, Leukemia L-1210, Lewis lung carcinoma, Yoshida sarcoma and Rat ascites hepatoma. It may be useful to prolong the survival time of warm-blooded animals afflicted with said tumors and/or minimize the growth of said tumors in said animals. It may also be employed for therapy of malignant lymphoma, leukemia, stomach tumor and hepatoma. The nitrosourea compound (I) can be used for pharmaceutical use in the form of a pharmaceutical preparation suitable for either oral or parenteral administration. The compound (I) may also be used in conjunction or admixture with a pharmaceutical excipient. The excipient selected must be the one which dose not react with the compound (I). Suitable excipients include, for example, gelatin, lactose, glucose, sodium chloride, starch, magnesium stearate, talcum, vegetable oil and so forth. Other known medicinal excipients may be employed. The pharmaceutical preparation may be a solid dosage form such as, for example, a tablet, a coated tablet, a pill or a capsule; or a liquid dosage form such as, for example, a solution, a suspension or an emulsion. Further, the compound (I) may be employed, for example, in the form of an injection or suppository when administered parenterally. The pharmaceutical preparation may be sterilized and/or may contain auxiliaries such as, for example, preserving and stabilizing agents. The dose of the compound (I) for pharmaceutical use depends on route of administration; the age, weight and condition of the patients; and particular diseases to be treated. In general, it may be used for pharmaceutical use at a dose of 0.1 to 15 mg/kg, especially 0.2 to 5 mg/kg, per day. Experiments Chemotherapeutic effects of the nitrosourea compounds of the invention on tumor cells in mice were investigated by the following methods and materials. (METHODS) (A) Preventive effect against the growth of Ehrlich ascites tumor: .iso6 tumor cells of Ehrlich ascites carcinoma were inoculated intraperitoneally into a group of five femal mice (ICR mice, body weight: 19 - 23 g). A test compound was dissolved in a physiological saline solution (In the case where CCNU was employed as the test compound, said compound was suspended in a physiological saline solution containing 0.1 % NIKKOL HCO-60 (trademark; a surface active agent manufactured by Nikko Chemicals Co. Ltd.)) and administered intraperioneally to the mice. The administration of the test compound was begun 24 hours after the inoculation of the tumor cells and performed once a day for 5 days. The volume of ascites in the treated mice were measured after 7 days of the experiment. (B) Effect on the life span of mice implanted with leukemic cells of L-1210: 105 leukemic cells of L-1210 were inoculated intraperitoneally into a group of four male mice (BDF1 mice, body weight: 19 - 23 g). A test compound was dissolved in a physiological saline solution and administered intraperitoneally to the mice. The administration of the test compound was begun 24 hours after the inoculation of the leukemic cells and performed once a day for 5 days. The survival days of the treated mice were observed. (COMPOUND TESTED) Compound Nos. Chemical Names (The compounds of the present invention) 1. 1-(2-chloroethyl)-1-nitroso-3-n-butyl-3-(methyl 3-deoxy-i-D-glucopyranosid-3-yl)urea 2. 1-(2-chloroethyl)-1-nitroso-3-isobutyl-3-(methyi 3-deoxy--D-glucopyranosid-3-yl ) urea 3. 1-(2-chloroethyl)-1-nitroso-3-methyl-3-(methyl 3-deoxy-#-D-glucopyranosid-3-yl)urea 4. 1-(2-chloroethyl)-1-nitroso-3-allyl-3-(methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea 5. 1-(2-chloroethyl)-1-nitroso-3-propargyl-3- (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea 6. 1-(2-chloroethyl)-1-nitroso-3-(2-methoxyethyl)-3 (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea (Known compounds) CCNU: 1-(2-chloroethyl)-1-nitroso-3-cyclohexylurea GANU: 1- (2-chloroethyl) 1-nitroso-3-fl- (D-gluco- pyranosyl)urea (RESULTS) The results of the experiments are shown in the following Tables 1 and 2. Table 1 Preventive effect against the growth of Ehrlich ascites carcinoma (Method A). Dose Ascites Inhibition Therapertic Compound (mg/kg/ volume(g) (b) (c) (d) (e) Nos. day) (a) ratio MTD MED index T/C (%) 100 - Toxic(4/5)* 50 0.0/4.2 100 12.5 0.0/4.2 100 1. 3.12 0.0/4.2 100 50 0.78 64 0.78 0.0/4.2 100 0.39 1.7/4.2 59.5 0.19 3.6/4.2 14.3 50 - Toxic (1/5)* 25 0.0/3.7 100 6.25 0.0/3.7 100 2. 1.56 0.0/3.7 100 25 0.195 128 0.39 0.0/3.7 100 0.195 0.0/3.7 100 0.097 3.4/3.7 8.1 50 - Toxic(1/5)* 25 0.0/3.7 100 6.25 0.0/3.7 100 3. 1.56 0.0/3.7 100 25 0.39 64 0.39 0.0/3.7 100 0.195 0.7/3.7 81.1 0.097 3.6/3.7 2.7 50 - Toxic (3/5)* 25 0.0/3.7 100 6.25 0.0/3.7 100 4. 1.56 0.0/3.7 100 25 0.195 128 0.39 0.0/3.7 100 0.195 0.0/3.7 100 0.097 2.6/3.7 29.7 Table 1 (continued) Dose Ascites Inhibition Therapertic Compound (mg/kg/ volume(g) (b) (c) (d) (e) Nos. day) (a) ratio MTD MED index T/C (%) 50 - Toxic(1/5)* 25 0.0/3.7 100 5. 6.25 0.0/3.7 100 25 0.78 32 1.56 0.0/3.7 100 0.78 0.0/3.7 100 0.39 2.4/3.7 35.1 50 - Toxic(2/5)* 25 0.0/3.7 100 6.25 0.0/3.7 100 6. 1.56 0.0/3.7 100 25 0.195 128 0.39 0.0/3.7 100 0.195 0.0/3.7 100 0.09.7 3.7/3.7 0.0 100 - Toxic(5/5)* 50 '0.0/5.7 100 CCNU 12.5 0.0/5.7 100 50 12.5 4 6.25 3.8/5.7 33.3 3.12 4.5/5.7 21.1 25 - Toxic(5/5)* 12.5 0.0/4.8 100 3.12 0.0/4.8 100 GANU 0.78 0.0/4.8 100 12.5 0.39 32 0.39 0.0/4.8 100 0.19 1.0/4.8 79.2 0.09 4.6/4.8 4.2 Note: (a) : T = the average volume of ascites in the treated mice C = the average volume of ascites in the untreated mice (control group of mice) (b) : Inhibition ratio (%) = C C T X 100 C (c) : MTD = Maximum Tolerated Dose (i.e., the maximum dose which shows 100 % inhibition for the growth of Ehrlich ascites tumor in mice without causing the death of said mice) (d) : MED = Minimum Effective Dose (i.e., the minimum dose which shows 100 % inhibition for the growth of said ascites tumor) (e) : Therapeutic index = MTD / MED * : the number of mice died / the number of mice used Table 2 Effect on life span of mice inplanted with Leukemia L-1210 (Method B). Compound Dose Mean survival ILS(%) 60-day No. (mg/kg/day) days(T/C)(a) (b) survivors(c) 25 60.0/7.1 745.1 4/4 1. 12.5 60.0/7.1 745.1 4/4 6.25 15.0/7.1 111.3 0/4 12.5 60.0/8.6 597.7 4/4 2. 6.25 60.0/8.6 597.7 4/4 3.12 13.5/8.6 57.0 0/4 12.5 60.0/8.4 614.3 4/4 3. 6.25 60.0/8.4 614.3 4/4 3.12 38.8/8.4 361.9 2/4 1.56 14.3/8.4 70.2 0/4 25 51.3/8.6 496.5 3/4 4. 12.5 60.0/8.6 597.7 4/4 6.25 15.5/8.6 80.2 0/4 Note : (a) : T = the mean survival days of the treated mice C = the mean survival days of the untreated mice (control group of mice) (b) : ILS(Increase in Life Span) = T - C X 100 C (c) : 60-day survivors = the number of mice survived for 60 days / the number of mice used Practical and presently-preferred embodiments of the present invention are illustratively shown -in the following Examples. Through out the specification and claims, the term "lower alkyl" and "lower alkoxy" should be interpreted as refering to straight or branched alkyl and alkoxy group having one to five carbon atoms, and the term "lower alkenyl" and "lower alkynyl" should be interpreted as refering to straight or branched alkenyl and alkynyl group having two to five carbon atoms. Example 1 (1) 2.5 g of methyl 2,3-anhydro-g-allopyranoside (J. Chem. Soc., 472 (1928)), 10 g of n-butylamine and 20 ml of ethanol are heated at 1500C for 30 hours in a sealed tube. The reaction mixture is concentrated under reduced pressure to dryness, whereby methyl 3-n-butylamino-3-deoxy-$-D-gluco- pyranoside is obtained as a crude product. Said crude product is dissolved in 40 ml of methanol, and 2.5 g of 2-chloroethyl isocyanate are dropwised thereto at a temperature of 0 to 50C. The mixture is stirred at room temperature for 1.5 hours. After the reaction, the mixture is evaporated under reduced pressure to remove solvent. The residue is purified by silica gel chromatography (Solvent; chloroform: benzene:methanol=5:2:1), whereby 3.0 g of 1-(2-chloroethyl)-3n-butyl-3-(methyl 1-deoxy-#-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. \Q)D25 + 106.50 (C = 1.23, methanol) IR Nujol (cm-Ú): 3400, 1670, 1615, 1520, 1040 NMR (d6-DMSO) # : 0.80 - 1,90 (m, 7H, -CH2CH2CH2CH2), 3.32 (s, 3H, OCH3), 4.64 (d, 1H, H1) (2) 1.8 g of 1-(2-chloroethyl)-3-n-butyl-3-(methyl 3 deoxy-#-D-glucopyranosid-3-yl)urea and one g of anhydrous sodium acetate are suspended in 40 ml of ethyl acetate, and 2.2 g of nitrogen tetroxide gas are introduced into the suspension at -100C for 10 minutes under stirring. The mixture is stirred at same temperature for 20 minutes. 6 ml of methanol are added to the reaction mixture and said mixture is further stirred for about 10 minutes. The reaction mixture is adjusted to pH 5 to 6 with an aqueous 20 % sodium carbonate solution. The organic layer is collected from the mixture, dried and evaporated under reduced pressure to remove solvent. The residue is purified by silica gel chromatography (Solvent; ethyl acetate: benzene:methanol=8:2:1), whereby 1.1 g of 1-(2-chloroethyl)-1-nitroso-3-n-butyl-3- (methyl 3-deoxy--D-glucopyranosid-3-yl)urea are obtained as yellow caramel. M.p. 500C (decomp.) []25 + 90.70 (C = 1.08, methanol) max. (cmÚ): 3450, 1680, 1040 NMR (d6-DMSO) #: 0.70 - 1.80 (m, 7H, -CH2CH2CH2CH2), 3.32 (s, 3H, OCH2), 4.62 (d, 1H, J=3Hz, H1) Example 2 {1) 2.5 g of methyl 2,3-anhydro-#-allopyranoside, 10 g of isobutylamine and 2.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby 2.7 g of 1-(2-chloroethyl)-3-isobutyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. [&alpha;]21D + 63.40 (C = 1.54, methanol) Nujol (cm-Ú): 3300, 1660, 1560, 1510, 1100, 1040 NMR (d6-DMSO) t: 0.88 (d,d, 6H, J= 6Hz, -CH(CH3)2, 3.33 (s, 3H, OCH3), 4.68 (d, 1H, J= 3Hz, H1) (2) 1.8 g of 1-(2-chloroethyl)-3-isobutyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.9 g of 1-(2-chloroethyl)-1-nitroso-3isobutyl-3-(methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea is obtained as yellow caramel. M.P. 53 C (decomp.) [&alpha;]18D + 84.20 (C = 1.22, methanol) IR Dujol (cm-Ú): 3440, 1690, 1070, 1040, 1010 NMR (d6-DMSO)#: 0.89 (d, 6H, J= 6.5Hz, -CH(CH3)2), 3.30 (s, 3H, OCH3), 4.64 (d, 1H, J= 2.5Hz, H) Example 3 (1) 5.2 g of methyl 2,3-anhydro-&alpha;-allopyranoside, 30 ml of 30 % methylamine-ethanol solution and 4.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby '1.6 g of 1-(2-chloroethyl)-3-methyl-3 (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. [&alpha;]18 + 123.70 (C = 0.88, methanol) NMR (d6-DMSO)t : 3.00 (s, 3H, -N-CH3), 3.32 (s, 3H, OCH3), 4.98 (d, 1H, J= 3Hz, H1), 6.52 (broad, 1H, -NH-) (2) 1.6 g of 1-(2-chloroethyl)-3-methyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.9 g of 1-(2-chloroethyl)-1-nitroso-3methyl-3-(methyl 3-deoxy-d-D-glucopyranosid-3-yl)urea are obtained as yellow caramel. M.P. 63 C (decomp.) [&alpha;]20D + 99.0 (C = 1.38, methanol) IR # Nujol (cm-Ú): 3400, 1710, 1545, 1080, 1055, 1030 NMR (d6-DMSO)3: : 3.00 (s, 3H, -N-CH3), 3.48 (s, 3H, OCH3), 4.96 (d, 1H, Jf 2.5Hz, H1) Example 4 (1) 2.5 g of methyl 2,3-anhydro-&alpha;-allopyranoside, 10 g of allylamine and 2.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby 2.1 g of 1-(2-chloroethyl)-3-allyl-3-(methyl 3-deoxy-d-D- glocopyranosid-3-yl)urea are obtained as colorless caramel. [&alpha;]21D + 102.30 (C = 1.09, methanol) @@(Nujol @@-Ú, 3300, 1670, 1640, 1510, 1040 max. NMR (d6-DMSO)#: 3.32 (s, 3H, OCH3), 4.67 (d, 1H, J= 3Hz, H1), 6.17 (broad, 1H, -NH-) (2) 1.7 g of 1-(2-chloroethyl)-3-allyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.9 g of 1-(2-chloroethyl)-1-nitroso3-allyl-3-(methyl 3-dcoxy-&alpha;-D-glocopyranosid-3-yl)urea is obtained as yellow caramel. M.p. 520C (decomp.) C) D * 90.4 (C = 1.28, methanol) IR)Nujol (cm-Ú): 3450, 1690, 1050, 1010 NMR (d6-DMSO)3: 3.33 (s, 3H, OCH3), 4.64 (d, 1H, J= 3Hz, H1) Example 5 (1) 2.5 g of methyl 2,3-anhydro-&alpha;-allopyranoside, 10 g of propargylamine and 2.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby 3.0 g of 1-(2-chloroethyl)-3-propargyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. [&alpha;]21D + 85.60 (C = 1.37, methanol) IR)Nujol (cm-Ú): 3280, 1670, 1640, 1520, 1040 NMR (d6-DMSO)#: 3.19 (s, 1H, -C CH), 3.34 (s, 3H, OCH3 ), 4.63 (d, 1H, J= 2Hz, H1), 6.54 (broad, 1H, -NH-) (2) 1.7 g of 1-(2-chloroethyl)-3-propargyl-3-(methyl 3 deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.8 g of 1-(2-chloroethyl)-1-nitroso-3 propargyl-3-(methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea is obtained as yellow caramel. M.p. 500C (decomp.) [&alpha;]D + 81.4 (C = 1.02, methanol) IR) Nujol (cm-Ú): 3450, 1690, 1070, 1040, 1010 NMR (d6-DMSO): 3.32 (s, 3H, OCH3), 4.66 (d, 1H, J= 3Hz, H1) Example 6 (1) 2.5 g of methyl 2,3-anhydro-M-allopyranoside, 10 g of 2-methoxyethylamine and 2.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby 3.4 g of 1-(2-chloroethyl)-3-(2-methoxyethyl)- 3- (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. [@}21 + 49.80 (C = 1.38, methanol) IR)Nujol (cm-Ú): 3300, 1670, 1625, 1590, 1515, 1040 NMR (d6-DMSO): 3.24 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 6.29 (broad, 1H, -NH-) (2) 1.8 g of 1-(2-chloroethyl)-3-(2-methoxyethyl)-3- (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.8 g of 1-(2-chloroethyl)1-nitroso-3-(2-methoxyethyl)-3-(methyl 3-deoxy-&alpha;-D-gluco- pyranosid-3-yl)urea is obtained as yellow caramel. M.p. 550C (decomp.) ( 18 + 105.6 (C = 1.03, methanol) IR)Nujol (cm-Ú): 3400, 1690, 1040, 1010 NMR (d6-DMSO)#: 3.23 (s, 3H, OCH3), 3.33 (s, 3H, OCH3), 4.65 (d, 1H, J= 2.5Hz, H1) Example 7 (1) 2.5 g of methyl 2,3-anhydro-&alpha;-allopyranoside, 10 g of 3-methoxy-n-rpopylamine and 2.5 g of 2-chloroethyl isocyanate are treated in the same manner as described in Example 1-(1), whereby 4.0 g of 1-(2-chloroethyl)-3-(3-methoxy-n-propyl)3-(methyl 3-deoxy-t-D-glucopyranosid-3-yl)urea are obtained as colorless caramel. [&alpha;]19D + 76.3 (C = 1.3, methanol) IR)Nujol (cm-Ú): 3280, 1670, 1045 NMR (d6-DMSO)#: 1.47 - 2.10 (m, 2H, -CH2CH2CH2-), 3.23 (s, 3H, OCH3), 3.33 (s, 3H, OCH3), 4.65 (d, 1H, J= 3Hz, H1), 6.3 (broad, 1H, -NH-) (2) 1.9 g of 1-(2-chloroethyl)-3-(3-methoxy-n-propyl)-3- (methyl 3-deoxy-&alpha;-D-glucopyranosid-3-yl)urea and 2.2 g of nitrogen tetroxide gas are treated in the same manner as described in Example 1-(2), whereby 0.7 g of 1-(2-chloroethyl) 1-nitroso-3-(3-methoxy-n-propyl)-3-(methyl 3-deoxy-&alpha;-D-gluco- pyranosid-3-yl)urea is obtained as yellow caramel. M.p. 500C (decomp.) [&alpha;] D + 196.9 (C = 1.05, methanol) -1 max. (cm ): 3400, 1620, 1040 NMR (d6-DMSO)J: 1.65 - 2.10 (m, 2H, -CH2CH2CH2-), 3.21 (s, 3H, OCH3), 3.33 (s, 3H, OCH3), 4.65 (d, 1H, J= 3Hz, H1)

Claims: Claims: 1. Nitrosourea derivatives of the formula: EMI21.1 wherein R1 is lower alkyl and R2 is lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy-lower alkyl. 2. The compound of Claim 1, in which R1 is methyl. 3. The compound of Claim 1, in which R2 is methyl, n-butyl, isobutyl, allyl, propargyl, methoxyethyl or 3methoxy-propyl. 4. The compound of Claim 1, in which R1 is methyl, and R2 is methyl, n-butyl, isobutyl, allyl, propargyl, methoxyethyl or 3-methoxypropyl. 5. The compound of Claim 4, in which R1 is methyl and R2 is methyl. 6. The compound of Claim 4, in which R1 is methyl and R2is n-butyl. 7. The compound of Claim 4, in which R1 is methyl and R2 is isobutyl. 8. The compound of Claim4, in which R1 is methyl and R2is allyl. 9. The compound of Claim 4, in which R1 is methyl and R is propargyl. 10. The compound of Claim 4, in which RÚ is methyl and Rê is methoxyethyl. 11. A process for preparing a compound of the formula: EMI22.1 wherein R1 is lower alkyl and R2 is lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy-lower alkyl, which comprises subjecting a compound of the formula: EMI22.2 wherein R1 and R2 are the same as defined above, to nitrosation reaction. 12. The process according to Claim 11, wherein said nitrosation reaction is carried out by contacting the compound (II) with nitrous acid, nitrogen trioxide or nitrogen tetroxide at -200 to 200C in an inert solvent. 13. A therapeutic composition which comprises a therapeutically effective amount of a compound of the formula: EMI23.1 wherein R1 is lower alkyl and R2 is lower alkyl, lower alkenyl, lower alkynyl or lower alkoxy-lower alkyl, and a pharmaceutically acceptable carrier therefor.

Inventors: ARAI, YOSHIHISA, MORIKAWA, TAMIO, TSUJIHARA, KENJI
Applicants: TANABE SEIYAKU CO., LTD.
Application year: 1981
Main classification: C07H15
IPC codes: A61K31, C07H15, C07H13, A61P35